The overuse of radioactive iodine in low-risk papillary thyroid cancer patients
- PMID: 31196486
- DOI: 10.1016/j.suronc.2019.05.011
The overuse of radioactive iodine in low-risk papillary thyroid cancer patients
Abstract
Background: The aim of this study was to use current American Thyroid Association (ATA) management guidelines to identify groups who might be at risk of overtreatment with radioactive iodine (RAI) ablation after surgery for low-risk papillary thyroid cancer (PTC).
Methods: PTC patients were identified using the Surveillance, Epidemiology and End Results database. Characteristics of low-risk patients (defined as T1 without metastasis) were compared to those not low-risk. Predictors of receiving RAI for low-risk disease were determined using logistic regression.
Results: Of 32,229 cases, 17,286 (53.6%) were low-risk. Low-risk patients, compared to others, were older (mean age 51.3 versus 48.5 years), and more often female (81.6% versus 71.7%), white (69.7% versus 62.0%), and insured (87.6% versus 85.6%)(all p-values < 0.001). Nearly 25% of low-risk patients received RAI. Predictors of overtreatment with RAI included age <45 years (OR: 1.393; 95% CI: 1.250-1.552), age 45-64 years (OR: 1.275; 95% CI: 1.152-1.412), male sex (OR: 1.191; 95% CI: 1.086-1.305), Hispanic (OR: 1.236; 95% CI: 1.110-1.376) and Asian (OR: 1.306; 95% CI: 1.159-1.473) race, and extensive lymphadenectomy (OR: 1.243; 95% CI: 1.119-1.381).
Conclusion: Low-risk PTC patients were more likely to receive post-surgical RAI when not indicated under ATA guidelines if they were younger, male, Hispanic or Asian, or underwent extensive lymph node surgery. Identification of groups at risk for overtreatment can help impact practice patterns and improve the effective utilization of healthcare resources.
Keywords: Overtreatment; Radioactive iodine; Thyroid cancer.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients.Eur J Surg Oncol. 2019 Nov;45(11):2090-2095. doi: 10.1016/j.ejso.2019.06.025. Epub 2019 Jun 20. Eur J Surg Oncol. 2019. PMID: 31253543
-
Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?Auris Nasus Larynx. 2021 Feb;48(1):148-153. doi: 10.1016/j.anl.2020.07.005. Epub 2020 Jul 25. Auris Nasus Larynx. 2021. PMID: 32718811
-
Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.Thyroid. 2015 Apr;25(4):377-85. doi: 10.1089/thy.2014.0298. Epub 2015 Feb 6. Thyroid. 2015. PMID: 25578116
-
The role of radioactive iodine in the management of patients with differentiated thyroid cancer - An oncologic surgical perspective.Eur J Surg Oncol. 2020 May;46(5):754-762. doi: 10.1016/j.ejso.2020.01.010. Epub 2020 Jan 9. Eur J Surg Oncol. 2020. PMID: 31952928 Review.
-
Risk-oriented concept of treatment for intrathyroid papillary thyroid cancer.Best Pract Res Clin Endocrinol Metab. 2019 Aug;33(4):101281. doi: 10.1016/j.beem.2019.05.005. Epub 2019 Jun 4. Best Pract Res Clin Endocrinol Metab. 2019. PMID: 31208873 Review.
Cited by
-
Cross-sectional and prospective study on anti-Müllerian hormone changes in a cohort of pre-menopausal women with a history of differentiated thyroid cancer.Thyroid Res. 2020 Jan 10;13:1. doi: 10.1186/s13044-020-0075-z. eCollection 2020. Thyroid Res. 2020. PMID: 31938042 Free PMC article.
-
The age threshold of the 8th edition AJCC classification is useful for indicating patients with aggressive papillary thyroid cancer in clinical practice.BMC Cancer. 2020 Nov 30;20(1):1166. doi: 10.1186/s12885-020-07636-0. BMC Cancer. 2020. PMID: 33256657 Free PMC article.
-
Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.Front Endocrinol (Lausanne). 2022 Aug 11;13:960682. doi: 10.3389/fendo.2022.960682. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36034423 Free PMC article.
-
The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.Ann Nucl Med. 2021 Oct;35(10):1089-1099. doi: 10.1007/s12149-021-01644-1. Epub 2021 Jun 21. Ann Nucl Med. 2021. PMID: 34152569 Free PMC article.
-
Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival.Front Endocrinol (Lausanne). 2020 Oct 6;11:571421. doi: 10.3389/fendo.2020.571421. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33123090 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials